Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seoul National University Hospital
With
Gyeongsang National University Hospital
Korea Cancer Center Hospital
Seoul National University Boramae Hospital
Hallym University Medical Center
Inje University
Gangnam Severance Hospital
Chonbuk National University Hospital
Chungnam National University
The Catholic University of Korea
Wonju Severance Christian Hospital
Gachon University Gil Medical Center
Seoul National University Bundang Hospital
Multi-center trial, Phase II, non-randomized, open-label, single-arm study with combined therapy of bendamustine and rituximab in patients with MZBCL who has relapsed or progressive to prior chemotherapy or chemo-radiotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Histologically confirmed CD20-positive nodal or extranodal MZBCL
2. MZBCL patients who relapsed or progressed:
* At least one and a maximum of four prior lines of chemotherapy
* During or after the last chemotherapy or radiotherapy or
* Without progression within 6 months of the last dose of rituximab-based regimen
3. Patients age ≥ 18 years
4. ECOG PS 0-2
5. At least one bidimensionally measurable disease
6. Adequate hematologic, renal, and hepatic functions
7. Women of child-bearing potential should use two appropriate methods of contraception during the study
8. Written informed consent
2. Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks
3. Corticosteroids during last 28 days except chronic administration of prednisolone at a dose of \< 20mg/day for indications other than lymphomas
4. Evidence of CNS involvement by lymphomas
5. Active HBV/HCV infections, known HIV infection
6. Prior diagnosis of cancers within 5 years, except cervical intraepithelial neoplasia type 1, localized non-melanoma skin cancer, or small differentiated thyroid cancer
7. Serious concurrent disease:
8. Patients who are pregnant or lactating
Clareo Health | Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)
